Earnings results for BiondVax Pharmaceuticals (NASDAQ:BVXV)
BiondVax Pharmaceuticals Ltd. is estimated to report earnings on 11/24/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.01. The reported EPS for the same quarter last year was $-0.57.
BiondVax Pharmaceuticals last released its quarterly earnings results on August 20th, 2020. The reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $1.11. BiondVax Pharmaceuticals has generated ($3.60) earnings per share over the last year. BiondVax Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 24th, 2020 based off prior year’s report dates.
Analyst Opinion on BiondVax Pharmaceuticals (NASDAQ:BVXV)
Dividend Strength: BiondVax Pharmaceuticals (NASDAQ:BVXV)
BiondVax Pharmaceuticals does not currently pay a dividend. BiondVax Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: BiondVax Pharmaceuticals (NASDAQ:BVXV)
In the past three months, BiondVax Pharmaceuticals insiders have not sold or bought any company stock. Only 6.03% of the stock of BiondVax Pharmaceuticals is held by insiders. Only 4.14% of the stock of BiondVax Pharmaceuticals is held by institutions.
Earnings and Valuation of BiondVax Pharmaceuticals (NASDAQ:BVXV
Earnings for BiondVax Pharmaceuticals are expected to remain at ($0.06) per share in the coming year. The P/E ratio of BiondVax Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of BiondVax Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
More latest stories: here